{"version":"1.0","provider_name":"MedCity News","provider_url":"https:\/\/medcitynews.com","author_name":"Frank Vinluan","author_url":"https:\/\/medcitynews.com\/author\/fvinluan\/","title":"Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition - MedCity News","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Ey0g0rO0fo\"><a href=\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/\">Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-kelonia-acquisition-in-vivo-cell-therapy-cancer-multiple-myeloma-bcma-genetic-medicine-lly\/embed\/#?secret=Ey0g0rO0fo\" width=\"600\" height=\"338\" title=\"&#8220;Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition&#8221; &#8212; MedCity News\" data-secret=\"Ey0g0rO0fo\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2025\/09\/ImmuneCells_Tcells_NKcells_lymphocytes.jpg","thumbnail_width":803,"thumbnail_height":435,"description":"Kelonia Therapeutics brings to Eli Lilly an in vivo cell therapy in early clinical development for multiple myeloma. The deal complements Lilly\u2019s acquisitions of Verve Therapeutics and Orna Therapeutics in the past year, each taking different approaches to developing in vivo genetic medicines."}